AI-powered translational governance for biomedical portfolios.
This route compresses the deck into a cleaner web-native pitch: the problem, the market opportunity, the two-pillar solution, early validation, business model, and funding ask.
Great science. Poor translation.
Subjective review, binary decisions, weak risk modelling, and poor post-award governance leave biomedical portfolios capital-inefficient.
$240B+ annual biomedical R&D spend with low translation success.
Institutions need a system that improves commercialization throughput and governance quality without adding bureaucratic drag.
Evaluation engine + portfolio governance.
STRIDE.AI combines readiness scoring, risk quantification, stage-gate modelling, and live portfolio oversight.
Operational AI base with stakeholder interest.
The pitch is grounded in existing platform work, institutional demos, and a path toward funded validation.
Institutional SaaS with add-ons.
Core licensing expands with analytics, consulting, white-label deployment, and diligence/reporting support.
Use small non-dilutive funding to validate commercial deployment.
The ask funds commercial validation, regulatory and AI governance preparation, IP strategy, and pilot deployment planning.